Kidney cancer
89 results
1 - 89
Cytoreductive nephrectomy in metastatic renal cell carcinoma- Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
- Targeted therapy for advanced renal cell carcinoma
- Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer
- Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
- Immunotherapy for metastatic renal cell carcinoma
- Sex and gender as predictors for allograft and patient‐relevant outcomes after kidney transplantation
- Targeted therapy for metastatic renal cell carcinoma
- Partial nephrectomy versus radical nephrectomy for clinical localised renal masses
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients
- Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
- Belatacept for kidney transplant recipients
- Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients
- Steroid avoidance or withdrawal for kidney transplant recipients
- Synbiotics, prebiotics and probiotics for people with chronic kidney disease
- Bone‐modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta‐analysis
- Effects of exposure to night shift work on cancer risk in workers
- Surgical management for upper urinary tract transitional cell carcinoma: Cochrane systematic review
- Antihypertensive treatment for kidney transplant recipients
- Gemcitabine for unresectable, locally advanced or metastatic bladder cancer: Cochrane systematic review
- Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia
- Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
- Green tea (Camellia sinensis) for the prevention of cancer
- Darbepoetin for the anaemia of chronic kidney disease
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome
- Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies
- Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents
- Surgical management of localised renal cell carcinoma: Cochrane systematic review
- Erythropoiesis‐stimulating agents for anaemia in chronic heart failure patients
- Pharmacological interventions for pruritus in adult palliative care patients
- Physical exercise training interventions for children and young adults during and after treatment for childhood cancer
- Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
- Paracetamol (acetaminophen) for chronic non‐cancer pain in children and adolescents
- Platinum‐containing regimens for triple‐negative metastatic breast cancer
- Multimodal interventions for cachexia management
- First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis
- Chinese medicinal herbs to treat the side‐effects of chemotherapy in breast cancer patients
- Bisphosphonates for advanced prostate cancer
- Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease
- Platinum‐containing regimens for metastatic breast cancer
- Non‐surgical versus surgical treatment for oesophageal cancer
- Screening with urinary dipsticks for reducing morbidity and mortality
- Simple hysterectomy with pelvic lymphadenectomy versus radical hysterectomy with pelvic lymphadenectomy for women with stage IA2‐IB1 cervical cancer
- Iron therapy in anaemic adults without chronic kidney disease: Cochrane systematic review
- Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents
- Erythropoiesis‐stimulating agents for preventing acute kidney injury
- Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
- Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections
- Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients
- Erythropoietin or darbepoetin for patients with cancer
- Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients
- Interleukin 2 receptor antagonists for kidney transplant recipients
- Immunity after COVID‐19 vaccination in people with higher risk of compromised immune status: a scoping review
- Drugs for treating urinary schistosomiasis
- Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status
- HMG CoA reductase inhibitors (statins) for dialysis patients
- Dehydroepiandrosterone for systemic lupus erythematosus
- Cryotherapy for liver metastases
- Immunosuppressive treatment for proliferative lupus nephritis: Cochrane systematic review
- Rofecoxib for osteoarthritis
- Rofecoxib for rheumatoid arthritis
- Perioperative systemic nonsteroidal anti‐inflammatory drugs (NSAIDs) in women undergoing breast surgery
- Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for adrenal tumours in adults
- Decision coaching for people making healthcare decisions
- Antibody induction therapy for lung transplant recipients
- Interventions for dialysis patients with hepatitis C virus (HCV) infection
- Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
- Dietary advice with or without oral nutritional supplements for disease‐related malnutrition in adults
- Selenium supplementation for the primary prevention of cardiovascular disease: Cochrane systematic review
- Educational interventions for preventing lead poisoning in workers